Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JOIN-us joint outcomes study in hemophilia A or B on Elocta or Alprolix prophylaxis
2022-502921-16-00Phase 4Completed
- Sponsor
- Sobi
- Start
- Jun 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 4, open-label trial of efmoroctocog alfa and eftrenonacog alfa in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Sobi. Primary endpoint: Change from baseline in total HEAD-US score up to month 18. Started Jun 2023; status: completed.
02
Drugs
efmoroctocog alfaeftrenonacog alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2022-502921-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502921-16-00.